Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer

References

• Burris HA, II, Moore MJ, I, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403–2413
   PubMed Web of Science ®Google Scholar
• Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, et al. Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment?. Oncol Rep 2010; 23: 1183–1192
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960–1966
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825
   PubMed Web of Science ®Google Scholar
• Kim R. FOLFIRINOX: A new standard treatment for advanced pancreatic cancer?. Lancet Oncol 2011; 12: 8–9
   Google Scholar
• Pestieau SR, Stuart OA, Chang D, Jacquet P, Sugarbaker PH. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998; 84: 706–711
   PubMed Web of Science ®Google Scholar
• Engelhardt R. Hyperthermia and drugs. Recent results. Cancer Res 1987; 104: 136–203
   Google Scholar
• Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2’,2’-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995; 62: 627–630
   PubMed Web of Science ®Google Scholar
• Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 2009; 25: 210–219
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kokura S, Oyamada H, Inui T, Okita M, Isozaki Y, et al. Effects of a sequential combination of hyperthermia and gemcitabine in the treatment of advanced unresectable pancreatic cancer: A retrospective study. Thermal Med 2008; 24: 131–139
   Google Scholar
• Tschoep K, Boeck S, Berger F, Maier V, Adbel-Rahaman S, Kuhlencordt M, et al. Regional hyperthermia (RHT) combined with gemcitabine (GEM) + cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO phase II trial. J Clin Oncol 2008; 26: abstr4635
   Web of Science ®Google Scholar
• Song CW, Rhee JG, Lee CK, Levitt SH. Capacitive heating of phantom and human tumors with an 8 MHz radiofrequency applicator (Thermotron RF-8). Int J Radiat Oncol Biol Phys 1986; 12: 365–372
   PubMed Web of Science ®Google Scholar
• Lee CK, Song CW, Rhee JG, Levitt SH. Clinical experience with thermotron RF-8 capacitive heating for bulky tumors: University of Minnesota experience. Radiol Clin North Am 1989; 27: 543–558
   PubMed Web of Science ®Google Scholar
• Kato H, Hiraoka M, Nakajima T, Ishida T. Deep-heating characteristics of an RF capacitive heating device. Int J Hyperthermia 1985; 1: 15–28
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247
   Google Scholar
• Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimoto K, et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 2011; 29: abstr4007
   Google Scholar
• Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009; 27: 5660–5669
   PubMed Web of Science ®Google Scholar
• Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003; 34: 107–116
   PubMedGoogle Scholar
• Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79: 1516–1520
   PubMed Web of Science ®Google Scholar
• Kato H, Kondo M, Imada H, Kuroda M, Kamimura Y, Saito K, et al. QA committee report: Guidelines for safe heating by capacitive-type heating technique to treat patients with metallic implants. Thermal Medicine 2011; 27: 28–45
   Google Scholar
• Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia 42–43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975; 72: 937–940
   PubMed Web of Science ®Google Scholar
• Mella O, Dahl O. Timing of combined hyperthermia and 1,3-bis(2-chloroethyl)-1-nitrosourea or cis-diamminedichloroplatinum in BD IX rats with BT4A tumours. Anticancer Res 1985; 5: 259–263
   PubMed Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10: 463–468
   PubMed Web of Science ®Google Scholar
• Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243–3251
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 1996; 274: 784–787
   PubMed Web of Science ®Google Scholar
• Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272: 14914–14920
   PubMed Web of Science ®Google Scholar
• Adachi S, Kokura S, Okayama T, Handa O, Takagi T, Naito Y, et al. Hyperthermia cancels tumor-associated immune suppression. Gastroenterology 2008; 134: A–748
   Web of Science ®Google Scholar
• Lee CK, Song CW, Rhee JG, Foy JA, Levitt SH. Clinical experience using 8 MHz radiofrequency capacitive hyperthermia in combination with radiotherapy: Results of a phase I/II study. Int J Radiat Oncol Biol Phys 1995; 32: 733–745
   PubMed Web of Science ®Google Scholar
• Karasawa K, Muta N, Nakagawa K, Hasezawa K, Terahara A, Onogi Y, et al. Thermoradiotherapy in the treatment of locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1994; 30: 1171–1177
   PubMed Web of Science ®Google Scholar
• Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma, (2001). Int J Hyperthermia 2009; 25: 338–343
   PubMed Web of Science ®Google Scholar
• Jones E, Samulski TV, Leonard RP, Dewhirst MW. Hyperthermia4th. Lippincott Williams & Wilkins, Philadelphia 2003
   Google Scholar
• van der Zee J, Peer-Valstar JN, Rietveld PJ, de Graaf-Strukowska L, van Rhoon GC. Practical limitations of interstitial thermometry during deep hyperthermia. Int J Radiat Oncol Biol Phys 1998; 40: 1205–1212
   PubMed Web of Science ®Google Scholar
• Ohguri T, Yahara K, Moon SD, Yamaguchi S, Imada H, Terashima H, et al. Deep regional hyperthermia for the whole thoracic region using 8 MHz radiofrequency-capacitive heating device: Relationship between the radiofrequency-output power and the intra-oesophageal temperature and predictive factors for a good heating in 59 patients. Int J Hyperthermia 2011; 27: 20–26
   PubMed Web of Science ®Google Scholar
• Fatehi D, van der Zee J, Notenboom A, van Rhoon GC. Comparison of intratumor and intraluminal temperatures during locoregional deep hyperthermia of pelvic tumors. Strahlenther Onkol 2007; 183: 479–486
   PubMed Web of Science ®Google Scholar